Allergan Company Profile

✉ Email this page to a colleague

ALLERGAN has seventy-three approved drugs.

There are nine US patents protecting ALLERGAN drugs.

There are one hundred and eighty-one patent family members on ALLERGAN drugs in fifty-five countries and one hundred and sixteen supplementary protection certificates in eighteen countries.

International Patents:	181
US Patents:	9
Tradenames:	70
Ingredients:	54
NDAs:	73
Patent Litigation for Allergan:	See patent lawsuits for Allergan
PTAB Cases with Allergan as patent owner:	See PTAB cases with Allergan as patent owner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020490-001	Mar 13, 1997		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Allergan	OPHTHETIC	proparacaine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	012583-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Allergan	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	9,284,314	⤷ Try a Trial		Y		⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-002	Jul 3, 1996	5,202,128	⤷ Try a Trial
Allergan	DILACOR XR	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020092-003	May 29, 1992	4,839,177	⤷ Try a Trial
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020613-001	Sep 6, 1996	6,465,464*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Transdermal System Extended-re	3.9 mg/24 hrs	➤ Subscribe	2008-08-19
➤ Subscribe	Ophthalmic Solution	0.30%	➤ Subscribe	2007-07-19
➤ Subscribe	Tablets	2.5 mg, 5 mg, 10 mg, and 20 mg	➤ Subscribe	2011-12-19
➤ Subscribe	Sublingual Tablets	2.5 mg	➤ Subscribe	2017-07-27
➤ Subscribe	Capsules	4 mg and 8 mg	➤ Subscribe	2012-10-09
➤ Subscribe	Ophthalmic Solution	0.05%	➤ Subscribe	2008-10-14
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Sublingual Tablets	5 mg and 10 mg	➤ Subscribe	2013-08-13
➤ Subscribe	Extended-release Capsules	60 mg	➤ Subscribe	2009-03-02

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	300683	Netherlands	⤷ Try a Trial	PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1214076	SZ 49/2008	Austria	⤷ Try a Trial	PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
0600675	10C0036	France	⤷ Try a Trial	PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.